{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:06:50Z","timestamp":1790712410726,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,26]],"date-time":"2027-09-26T00:00:00Z","timestamp":1821916800000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA101642"],"award-info":[{"award-number":["T32CA101642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.09.014","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:11:52Z","timestamp":1790068312000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival associated with recommended risk-reducing interventions for individuals with pathogenic variants in BRCA1\/2"],"prefix":"10.1016","volume":"214","author":[{"given":"Isabel","family":"Beshar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viveros-Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Agusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni Nitecki","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.09.014_bb0010","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0015","series-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines","year":"2025"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0020","series-title":"Complications of Prosthetic Breast Reconstruction in Prophylactic Versus Therapeutic Mastectomy: A Systematic Review and Meta-Analysis","author":"Schelletter","year":"2025"},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pon.6111","article-title":"Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1\/2 pathogenic variant carriers","volume":"32","author":"Isselhard","year":"2023","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13053-022-00244-y","article-title":"Psychological factors and the uptake of preventative measures in BRCA1\/2 pathogenic variant carriers: results of a prospective cohort study","volume":"20","author":"Dick","year":"2022","journal-title":"Hered. Cancer Clin. Pract."},{"key":"10.1016\/j.ygyno.2026.09.014_bb0035","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1200\/PO.21.00233","article-title":"Systemic barriers to risk-reducing interventions for hereditary cancer syndromes: implications for health care inequities","volume":"5","author":"Mittendorf","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10549-019-05440-4","article-title":"Risk-reducing mastectomy in BRCA carriers: survival is not the issue","volume":"179","author":"Neven","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.014_bb0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of Cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12262-011-0307-5","article-title":"Randomised clinical trials in surgery: a look at the ethical and practical issues","volume":"73","author":"Das","year":"2011","journal-title":"Indian J. Surg."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.014_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3747\/co.25.3770","article-title":"Screening for breast Cancer in 2018\u2014what should we be doing today?","volume":"25","author":"Seely","year":"2018","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.014_bb0060","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","article-title":"The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time Bias in real-world data using a surgical oncology example","volume":"31","author":"Duchesneau","year":"2022","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2026.09.014_bb0065","author":"National Comprehensive Cancer Network"},{"issue":"14","key":"10.1016\/j.ygyno.2026.09.014_bb0070","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.014_bb0075","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaoncol.2024.2185","article-title":"BRCA1, BRCA2, and associated cancer risks and management for male patients: a review","volume":"10","author":"Cheng","year":"2024","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.014_bb0090","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast Cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.breastdis.2013.01.034","article-title":"Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis","volume":"24","author":"Lee","year":"2013","journal-title":"Breast Dis. Year b. Q."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI surveillance and breast Cancer mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.014_bb0105","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ijc.29534","article-title":"Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)","volume":"137","author":"Saadatmand","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13244-024-01653-4","article-title":"The paradox of MRI for breast cancer screening: high-risk and dense breasts\u2014available evidence and current practice","volume":"15","author":"Sardanelli","year":"2024","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12916-024-03258-6","article-title":"Isolating the effect of confounding from the observed survival benefit of screening participants \u2014 a methodological approach illustrated by data from the German mammography screening programme","volume":"22","author":"Buschmann","year":"2024","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0969141315597959","article-title":"Correction factors for self-selection when evaluating screening programmes","volume":"23","author":"Spix","year":"2016","journal-title":"J. Med. Screen."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0125","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cncr.29805","article-title":"Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status","volume":"122","author":"Haas","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/curroncol31010023","article-title":"Counselling framework for germline BRCA1\/2 and PALB2 carriers considering risk-reducing mastectomy","volume":"31","author":"Wong","year":"2024","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.014_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41416-023-02503-8","article-title":"Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis","volume":"130","author":"Metcalfe","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0140","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"2019","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.014_bb0145","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.014_bb0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","article-title":"Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral","volume":"142","author":"Ingham","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.014_bb0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2026.09.014_bb0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjsurg.2023.10.011","article-title":"BRCA1\/2 mutation carriers & risk reducing mastectomy: who undergoes surgery and potential benefits","volume":"227","author":"Record","year":"2024","journal-title":"Am. J. Surg."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.014_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111991","article-title":"Uptake of breast cancer risk-management strategies among unaffected BRCA 1\/2 carriers: a systematic review of international evidence","volume":"52","author":"Godino","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.09.014_bb0175","series-title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality","author":"Domchek","year":"2026"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0180","article-title":"Survival outcomes with or without risk-reducing mastectomy in BRCA1 and BRCA2 pathogenic variant carriers","author":"Gandhi","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.014_bb0185","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jamasurg.2025.5929","article-title":"Risk-reducing bilateral mastectomy and mortality in carriers of BRCA1 and BRCA2 variants: a systematic review and meta-analysis","volume":"161","author":"O\u2019Reilly","year":"2026","journal-title":"JAMA Surg."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.014_bb0190","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time Bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"issue":"10218","key":"10.1016\/j.ygyno.2026.09.014_bb0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ygyno.2026.09.014_bb0200","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast Cancer: report of the National Surgical Adjuvant Breast and bowel project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"18","key":"10.1016\/j.ygyno.2026.09.014_bb0205","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast Cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and bowel project (NSABP-P1) breast Cancer prevention trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.014_bb0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41416-021-01597-2","article-title":"Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer","volume":"126","author":"Guzm\u00e1n-Arocho","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.014_bb0215","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.bjc.6600064","article-title":"Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations","volume":"86","author":"Duffy","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0220","series-title":"Prevention of ER-Negative Breast Cancer","author":"Li","year":"2014"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0225","doi-asserted-by":"crossref","first-page":"23690","DOI":"10.1038\/s41598-024-74746-1","article-title":"Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis","volume":"14","author":"Huang","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.014_bb0230","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement","volume":"322","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0235","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"2018","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0240","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00142","article-title":"Long-term survival in high-grade serous ovarian cancer compared with the general US population: a 30-year landmark analysis","volume":"3","author":"De Vitis","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"10.1016\/j.ygyno.2026.09.014_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103862","article-title":"Survival feature and trend of female breast cancer: a comprehensive review of survival analysis from cancer registration data","volume":"79","author":"Tang","year":"2025","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.014_bb0250","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0255","author":"Ranji"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/GME.0000000000001421","article-title":"What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?","volume":"27","author":"Hickey","year":"2020","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0265","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of Salpingectomy with Delayed Oophorectomy Versus Salpingo-oophorectomy with Quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.014_bb0270","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.22026","article-title":"Patient-Centered approach to surgical prevention of ovarian Cancer: a nonrandomized clinical trial","volume":"9","author":"Lu","year":"2026","journal-title":"JAMA Netw. Open"},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2026.09.014_bb0275","doi-asserted-by":"crossref","first-page":"TPS10615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10615","article-title":"NRG-CC008: a nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]","volume":"40","author":"Huh","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.014_bb0280","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.014_bb0285","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0290","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0295","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","article-title":"Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"301","author":"Huber","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.33531","article-title":"Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses\u2019 Health Studies","volume":"149","author":"Yang","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104770","article-title":"The levonorgestrel intrauterine device and ovarian cancer risk: a population-based study","volume":"36","author":"Shore","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann. Epidemiol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.014_bb0320","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.24.00176","article-title":"Hormonal contraception and breast Cancer risk for carriers of germline mutations in BRCA1 and BRCA2","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.014_bb0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/humupd\/dmac038","article-title":"Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: a systematic review and meta-analysis","volume":"29","author":"Van Bommel","year":"2023","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0330","article-title":"Society of Family Planning Clinical Recommendation: contraceptive considerations for individuals with cancer and cancer survivors part 2 \u2013 breast, ovarian, uterine, and cervical cancer: joint with the Society of Gynecologic Oncology","volume":"147","author":"Batur","year":"2025","journal-title":"Contraception"},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.014_bb0335","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28000","article-title":"Differences in breast and colorectal Cancer screening adherence among women residing in urban and rural communities in the United States","volume":"4","author":"Shete","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.014_bb0340","article-title":"Barriers of care to ovarian Cancer: a scoping review","volume":"15","author":"Rizvi","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.014_bb0345","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10897-009-9245-9","article-title":"Women\u2019s decision making about risk-reducing strategies in the context of hereditary breast and ovarian Cancer: a systematic review","volume":"18","author":"Howard","year":"2009","journal-title":"J. Genet. Couns."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0350","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast Cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.014_bb0355","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.30621","article-title":"Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors","volume":"123","author":"Cragun","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.09.014_bb0360","series-title":"Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)","author":"Sharma","year":"2026"},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.014_bb0365","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433576","article-title":"Novel cancer prevention strategies in individuals with hereditary cancer syndromes: focus on BRCA1, BRCA2, and Lynch syndrome","volume":"44","author":"Bowen","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.014_bb0370","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of Type and Location of BRCA1 and BRCA2 mutations with risk of breast and ovarian Cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.014_bb0375","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1200\/JCO.23.00295","article-title":"Comprehensive inherited risk estimation for risk-based breast Cancer screening in women","volume":"42","author":"Mars","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.014_bb0380","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool\u2014a web Interface for the prediction of breast and ovarian Cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.014_bb0385","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.014_bb0390","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41523-025-00820-0","article-title":"Polygenic risk score for breast cancer risk prediction in Asian BRCA1 and BRCA2 pathogenic variants carriers","volume":"11","author":"Tai","year":"2025","journal-title":"Npj Breast Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:40Z","timestamp":1790709580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":78,"alternative-id":["S0090825826021396"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival associated with recommended risk-reducing interventions for individuals with pathogenic variants in BRCA1\/2","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}